Infectious Disease Therapeutics Market size valued USD 121.4 billion in 2021 and expected to reach USD 166.32 billion by 2028, at a CAGR of 4.6% during the forecast period 2022-2028. Infectious diseases are caused by organisms, such as bacteria, virus, fungi or parasites. Many organisms live in our body but few of them cause diseases. These infectious diseases are transmitted from one individual to other either by direct or indirect contact. The drugs used for infectious diseases are antibiotics, antiviral, and antiparasitic, among others. Infectious disease therapeutics acts directly on organisms or helps the body system to fight infections. Infectious diseases include HIV, malaria, tuberculosis, hepatitis, and influenza, among others. Market players focus on mergers, acquisitions and collaborations to increase revenue share in the market. For instance, in August 2016, Pfizer acquired AstraZenecaâ€™s late-stage small molecule anti-infectives business for development and commercialization outside the U.S. In addition, market players investing on research and development to introduce new drugs and to strengthen their position in the infectious disease therapeutics market. Some of the pipeline anti-infectives include avycaz (ceftazidime and avibactam), bictegravir (Anti HIV), cabotegravir (Anti HIV). Patent expiry of blockbuster anti-infectives such as Tamiflu, cubicin and ambisome are expected to negatively effect the infectious disease therapeutics market. Key Developments: In July 2017, Gileadâ€™s â€œvoseviâ€ oral tablet was approved by U.S. FDA for treatment of adults with chronic hepatitis C virus In March 2015, U.S. Food and Drug Administration approved cresemba (isavuconazonium sulfate), a novel antifungal drug for treat adults with invasive aspergillosis and invasive mucormycosis, rare but serious infections In December 2014, Sanofi Pasteur announces FDA approval of fluzone intradermal quadrivalent (Influenza Vaccine) for adults.
Fastest Growing Market
Infectious disease therapeutics market is driven by the growing prevalence rates of infectious diseases, increased healthcare expenditure and increased funding of governments on prevention and management of infectious diseases. In addition, increased geriatric population and use of direct acting antiviral drugs are fuelling the growth of infectious diseases therapeutics market. However, patent expiry of many infectious disease drugs and increase number of generic alternatives hindering the market revenue of infectious disease therapeutics market.
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.